Orthostatic Dysregulation
Conditions
Interventions
Group A receives Hangebyakujutenmato in the I stage and midodrine hydrochloride in the II stage. Phase I and Phase II are 4 weeks each. There will be a 2-4 week washout period between Phase I and Phas
Sponsors
Saijo central hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: When all of the following are satisfied 1) Persons who have obtained written consent for participation in the research 2) 7 years old or older and under 18 years old at the time of obtaining consent 3) Those who have been diagnosed with orthostatic dysregulation by a doctor and whose symptoms are not improved by non-drug therapy
Exclusion criteria
Exclusion criteria: When one or more of the following are satisfied 1) Those who cannot discontinue other treatments that may affect the symptoms of orthostatic dysregulation 2) Those who suffering from acute diseases such as upper respiratory tract inflammation and acute gastroenteritis 3) Those who cannot exclude underlying diseases other than orthostatic dysregulation 4) Those who have difficulty communicating 5) Others who the principal investigator deems inappropriate as a subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate of subjective symptom visual analogue scale (VAS) score | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events, Blood Pressure and Pulse in New Orthostatic Test | — |
Countries
Japan
Contacts
Public ContactKoji Nishimura
Saijo central hospital Pediatrics
Outcome results
None listed